Researchers from the USA used commercially available electrodes for closed-loop spinal cord stimulation in three individuals with transtibial amputation.
Shares of Vertex Pharmaceuticals Inc. (VRTX) are progressing more than 9 percent on Wednesday morning trade after reporting positive results for its phase 2 study of VX-548 for the painful diabetic peripheral neuropathy.
Interventional spine and pain specialist William Porter McRoberts, MD, returns to Holy Cross Medical Group in Ft. Lauderdale, FL. He has performed over 55,000 s
The rise in diabetic neuropathy over the last few decades has paralleled the obesity and related diabetes pandemics, one expert says, and neurologists have a role to play in controlling it.
Purpose: This study aims to determine the effects of SGLT2 inhibitors on corneal dendritic cell density and corneal nerve measures in type 2 diabetes. Methods: Corneal dendritic cell densities and nerve parameters were measured in people with type 2 diabetes treated with SGLT2 inhibitors (T2DM-SGLT2i) [n = 23] and those not treated with SGLT2 inhibitors (T2DM-no SGLT2i) [n = 23], along with 24 age and sex-matched healthy controls. Results: There was a reduction in all corneal nerve parameters in type 2 diabetes groups compared to healthy controls (All parameters: p < 0.05). No significant differences in corneal nerve parameters were observed between T2DM-SGLT2i and T2DM-no SGLT2i groups (All parameters: p > 0.05). Central corneal dendritic cells were significantly reduced [mature (p = 0.03), immature (p = 0.06) and total (p = 0.002)] in the T2DM-SGLT2i group compared to the T2DM-no SGLT2i group. Significantly, higher mature (p = 0.04), immature (p = 0.004), total (p = 0.002) dend